Ratings 4D Molecular Therapeutics, Inc.

Equities

FDMT

US35104E1001

Real-time Estimate Cboe BZX Other stock markets 11:14:43 2024-04-25 am EDT			5-day change	1st Jan Change
23.78 ^USD	-1.96%		-3.43%	+18.11%

Apr. 15	Barclays Starts 4D Molecular Therapeutics With Overweight Rating, $45 Price Target	MT
Apr. 15	RBC Raises Price Target on 4D Molecular Therapeutics to $40 From $35, Keeps Outperform Rating, Speculative Risk Qualifier	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental situation
According to Refinitiv, the company's ESG score for its industry is poor.

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
The company's "enterprise value to sales" ratio is among the highest in the world.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
4D MOLECULAR THERAPEUTICS, INC.	+18.11%	1.24B	C-
IQVIA HOLDINGS INC.	+1.02%	43.84B	B
MODERNA, INC.	+4.38%	41.68B	B-
LONZA GROUP AG	+45.49%	41.25B	A
CELLTRION, INC.	-10.92%	27.04B	C
ICON PUBLIC LIMITED COMPANY	+7.25%	25.53B	B-
ALNYLAM PHARMACEUTICALS, INC.	-25.75%	18.18B	B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-4.24%	12.29B	C+
MEDPACE HOLDINGS, INC.	+25.58%	12.29B	C+
UNITED THERAPEUTICS CORPORATION	+6.86%	11.15B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes